In a randomized controlled trial (E-LIFT) in patients with DMT2 and NAFLD, empagliflozin reduced the serum ALT activity (−10.9 IU/L; p = 0.005) and reduced the amount of liver fat assessed with MRI-PDFF. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.